Moderna, Inc.
MRNANasdaqFull coverage
Latest dossier
AI-generated
General research and analysis by Moatsight, not personalized investment advice. We show, you decide. Disclaimers
Q3 of fiscal year 2026 · Published Nov 10, 2026,
Moderna sells mRNA vaccines against COVID-19, RSV and flu to US wholesalers and pharmacies and to governments abroad, and shares with Merck an individualised cancer therapy, intismeran, that met its Phase 3 goals in melanoma in 2026. Third-quarter 2026 revenue rose 29% to $1.3 billion, all of the growth from multi-year contracts with the UK, Canada and Australia, while US sales were flat and costs fell by about a fifth. The raised 2026 outlook implies a much weaker fourth quarter, and free cash flow over the last twelve months was minus $1.97 billion. Moatsight estimates revenue of about $2.47 billion over the next four quarters and free cash flow of about minus $1.36 billion, so how large intismeran becomes is what decides the company's future.
What you pay
| Figure | At the close | 5-yr median | 5-yr range |
|---|---|---|---|
| P/E | No value: no close yet | No value: no price history | |
| EV/Sales | No value: no close yet | No value: no price history | |
| EV/EBITDA | No value: no close yet | No value: no price history | |
| Price/FCF | No value: no close yet | No value: no price history | |
| Market cap | No value: no close yet | ||
| Net debt and other claims(enterprise value minus market cap) | No value: no close yet | ||
| Enterprise value | No value: no close yet |
How the business is doing
| Figure | Last 12 months | 1-year change1-year | Yearly, 3 years | 8 quarters |
|---|---|---|---|---|
| Revenue | $2.5B | +13.1%(better for the company) | −34.8% | Each quarter is listed in the row's details. |
| Diluted EPS | −$6.96 | n/m, not meaningful: from zero or below | n/m, not meaningful: from zero or below | Each quarter is listed in the row's details. |
| Free cash flow | −$2B | n/m, not meaningful: from zero or below | n/m, not meaningful: from zero or below | Each quarter is listed in the row's details. |
| Gross margin | 28.0% | −20.3 pp(worse for the company) | −3.2 pp | Each quarter is listed in the row's details. |
| Operating margin | −116.0% | +39.1 pp(better for the company) | −28.9 pp | Each quarter is listed in the row's details. |
| Net margin | −110.5% | +29.2 pp(better for the company) | −24.2 pp | Each quarter is listed in the row's details. |
| Share count | 430.000M | No value: cannot be derived | No value: cannot be derived | Each quarter is listed in the row's details. |
How to read these figures
- Last 12 months: the latest four reported quarters added up, or a figure computed from them. The share count is its latest quarter's average.
- 1-year change: the last 12 months against the 12 months a year earlier. A margin's change is in percentage points (pp). On a Next 12 months row, it is Moatsight's estimate against the last 12 months.
- Yearly, 3 years: the yearly rate over the last 3 years, compounded. For a margin, its average change a year in percentage points.
- 8 quarters: the last 12 months at each of the latest 8 quarter ends, oldest on the left; the dot is the latest. The quarters themselves are on Financials.
- n/m: not meaningful, such as a rate of change from a loss.
- Color: a 1-year change in the gain color is better for the company, one in the loss color worse. The caret and the sign show which way it moved, and a row where lower is better says so in its details. Color judges the company's reported results, never its share price or Moatsight's estimates, and no other column is colored.
Price
No closing prices are stored for this listing yet.
Facts
- Exchange
- Nasdaq · USD
- Kind
- Common stock
- Security
- Common Stock